Institutions / HighVista Strategies LLC
HighVista Strategies LLC
CIK 1335325 · Institution · as of Mar 31, 2026
Portfolio value
$362.16M
Positions
156
As of
Mar 31, 2026
Portfolio trend
Portfolio value
$362.16M-6.7%Positions
156+7.6%Top holdings
Mar 31, 2026View all 156 →
| Company | Value | % of portfolio |
|---|---|---|
| Invesco Db Commdy Indx Trck | $30.61M | 8.5% |
| Abivax SA | $12.61M | 3.5% |
| Praxis Precision Medicines, Inc. | $8.48M | 2.3% |
| Cogent Biosciences, Inc. | $7.58M | 2.1% |
| Spyre Therapeutics, Inc. | $7.38M | 2.0% |
| Vaxcyte, Inc. | $7.24M | 2.0% |
| Revolution Medicines, Inc. | $6.74M | 1.9% |
| Terns Pharmaceuticals, Inc. | $6.03M | 1.7% |
| Structure Therapeutics Inc.GPCR | $5.97M | 1.6% |
| Nuvalent, Inc. | $5.80M | 1.6% |
| Immunovant, Inc.IMVT | $5.59M | 1.5% |
| Soleno Therapeutics, Inc. | $5.53M | 1.5% |
| Tyra Biosciences, Inc. | $5.03M | 1.4% |
| Amylyx Pharmaceuticals, Inc. | $4.89M | 1.4% |
| Amazon.com Inc | $4.66M | 1.3% |
| Lb Pharmaceuticals IncLBRX | $4.28M | 1.2% |
| Relay Therapeutics, Inc. | $4.20M | 1.2% |
| Insmed Inc | $3.98M | 1.1% |
| NVIDIA Corp | $3.91M | 1.1% |
| Oruka Therapeutics, Inc. | $3.87M | 1.1% |
| Cytokinetics Inc | $3.87M | 1.1% |
| Liquidia CorpLQDA | $3.76M | 1.0% |
| Ocular Therapeutix, Inc | $3.74M | 1.0% |
| Tarsus Pharmaceuticals, Inc. | $3.68M | 1.0% |
| BridgeBio Pharma, Inc. | $3.68M | 1.0% |
Activity
Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Trim | Cogent Biosciences, Inc. Common stock | $-5.37M | -140K -41.47% | 197,051 2.09% of portfolio | medium |
| Q1 2026 as of | Exit | 171757206 Common stock | $-5.06M | -23K -100.00% | 0 | medium |
| Q1 2026 as of | Trim | Revolution Medicines, Inc. Common stock | $-4.95M | -51K -42.36% | 69,309 1.86% of portfolio | low |
| Q1 2026 as of | Exit | Arcellx, Inc. Common stock | $-4.89M | -75K -100.00% | 0 | low |
| Q1 2026 as of | Trim | Viridian Therapeutics, Inc. Common stock | $-4.66M | -238K -63.96% | 134,229 0.72% of portfolio | low |
| Q1 2026 as of | Add | 00370M103 Common stock | $4.57M | +41K +56.89% | 113,254 3.48% of portfolio | low |
| Q1 2026 as of | Trim | Apogee Therapeutics, Inc. Common stock | $-4.50M | -53K -59.92% | 35,761 0.83% of portfolio | low |
| Q1 2026 as of | Trim | Protagonist Therapeutics Inc Common stock | $-4.18M | -40K -53.97% | 33,852 0.99% of portfolio | low |
| Q1 2026 as of | Exit | Agios Pharmaceuticals, Inc. Common stock | $-4.02M | -148K -100.00% | 0 | low |
| Q1 2026 as of | New | Oruka Therapeutics, Inc. Common stock | $3.87M | +79K | 78,911 1.07% of portfolio | low |